

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/47		A1	(11) International Publication Number: WO 97/13515
(21) International Application Number: PCT/JP96/02850			(43) International Publication Date: 17 April 1997 (17.04.97)
(22) International Filing Date: 1 October 1996 (01.10.96)			(81) Designated States: AU, CA, CN, KR, MX, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority Data:	7/263896 8/57337	12 October 1995 (12.10.95) 14 March 1996 (14.03.96)	JP
(71) Applicant (for all designated States except US): OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 9, Kanda-Tsukasacho 2-chome, Chiyoda-ku, Tokyo 101 (JP).			Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(72) Inventors; and (75) Inventors/Applicants (for US only): URASHIMA, Hiroki [JP/JP]; 2715-3, Shioya, Ako-shi, Hyogo 678-02 (JP). TAKEJI, Yasuhiro [JP/JP]; 3150, Sakoshi, Ako-shi, Hyogo 678-01 (JP). SHINOHARA, Hisashi [JP/JP]; 13-1, Omiya-cho 1-chome, Gifu-shi, Gifu 500 (JP). FUJISAWA, Shigeki [JP/JP]; 72-5, Yonedacho Shima, Takasago-shi, Hyogo 676 (JP).			
(74) Agents: ASAMURA, Kiyoshi et al.; Room 331, New Otemachi Building, 2-1, Otemachi 2-chome, Chiyoda-ku, Tokyo 100 (JP).			

(54) Title: CARBOSTYRIL DERIVATIVE FOR CURING OPHTHALMOLOGICAL DISEASES

(57) Abstract

The present invention provides an agent for curing ophthalmological diseases which contains, as the active ingredient, a carbostyryl derivative or salt thereof represented by general formula (I), wherein R is a halogen atom, particularly the invention provides effective agent for curing xerophthalmia (dry eye) syndrome.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TC	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DESCRIPTION


CARBOSTYRIL DERIVATIVE FOR CURING OPHTHALMOLOGICAL DISEASES

FIELD OF THE INVENTION

The present invention relates to an agent for curing ophthalmological diseases which contains, as the effective ingredient, a carbostyryl derivative or salt thereof. More particularly, the present invention relates to an agent for curing ophthalmological diseases, especially xerophthalmia syndrome, commonly called as "dry eye" which contains, as the effective ingredient, a carbostyryl derivative or salt thereof represented by the general formula (I),



(wherein R is a halogen atom, the substituted position of the side-chain of the formula,



is 3- or 4-position in the carbostyryl skeleton, and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or a double bond), more preferably 2-(4-chlorobenzoylamino)-3-(2-5 quinolon-4-yl)propionic acid or salt thereof.

BACKGROUND ART

The carbostyryl derivatives represented by the general formula (I) and process for producing the same are described in Japanese Patent Publication No. 10 63-35623, the usefulness of carbostyryl derivatives as anti-gastric ulcer agents is described in Japanese Patent Application Kokai (Laid-open) No. 3-74329, and processes for producing those carbostyryl derivatives having optical activities are described in Japanese 15 Patent Application Kokai (Laid-open) No. 3-145468.

Further, the inhibitory effect of carbostyryl derivatives of the present invention on reactive oxygen metabolites is described in Japan. J. Pharmacol., Vol. 49, pp. 441-448 (1969), and the protectability of 20 gastric mucous membrane by carbostyryl derivatives of the present invention is described in Folia Pharmacol. Japon., Vol. 97, pp. 371-380 (1991).

Furthermore, the usefulness of carbostyryl derivatives as agents for curing diabetes mellitus is 25 described in International Publication No. WO 92/21342, the usefulness of carbostyryl derivatives as agents for protecting the intestinal mucosa from disorders is

described in International Publication No. WO 94/12182, and the usefulness of carbostyryl derivatives as agents for inhibiting the reduction in secretion of somatostatin is described in International Publication No.

5 WO 93/24043.

"Dry eye" symptom (xerophthalmia) is a pathogenic state (pathema) of the eye in which the surface of the eye cannot be maintained to normal condition due to a shortage of the amount of tears. Furthermore, the 10 mucous membranes (the epithelia of the cornea and conjunctiva) on the surface of the eye may be caused not only by an abnormal shortage of the amount of tears, but also by an abnormal nature of tears [Cf. DORAI-AI (dry eye), page 11, by Kazuo TSUBOTA, published from 15 NIPPON-HYÔRONSHA]. In addition to the above, such dry eye symptoms may be observed in case of Sjögren's syndrome with abnormal states (the amount and nature) of tears. Also, there have been known that the dry eye symptom may be occurred in the end-stage of Stevens- 20 Johnson syndrome and observed that the cornea and conjunctiva are injured.

Tear fluid (lacrima) is a very thin liquid layer having 7 μm in thickness, which covers the outmost (extima) layer of the front of eye, and having 25 trilaminar structure consisting of lipid layer, aqueous layer and mucoid layer. The lipid layer being existed on the outmost surface layer of the tear fluid is an oily film, which is produced and secreted mainly from

the meibomian glands located in periphery of the eyelids, and covers all over the aqueous layer. The lipid layer is considered to have the function for preventing evaporation of water from the aqueous layer.

5 The aqueous layer is a portion of so-called "tears" which occupies the most thickness of the tear fluid layer, and 98% of the constituent thereof is water. A pathogenic state in decreasing of the amount of this aqueous layer is so-called as "dry eye" symptom. The 10 mucoid layer covers the hydrophobic surface of the epithelium of the cornea, this mucoid layer changes the hydrophobic surface of the epithelium of the cornea to hydrophilic nature to maintains and extends the aqueous layer in the tear fluid, so that the aqueous layer can 15 be able to maintain on the surface of the epithelium of the cornea. Cells related to producing said mucoid layer are goblet cells being contained in the conjunctiva.

As explained above, the tear fluid which may 20 cause directly to introduce the "dry eye" symptom is involved in various tissue cells. Also the concept of "dry eye" symptom is complicated, so that a common type of eye drop preparation can only gives a temporary medical measure, thus at the present stage fundamental 25 method for medical treatment of the "dry eye" symptom have not been found yet. So that new method and new agent for curing the "dry eye" symptom have been eagerly expected.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a figure relating to the effect of carbostyryl derivative of the present invention against the amount of mucoid substance covering the conjunctiva in normal rabbits determined by Alcian blue binding method.

Fig. 2 shows a figure relating to the effect of carbostyryl derivative of the present invention against the number of goblet cells in normal rabbits.

Fig. 3 shows a figure relating to the effect of carbostyryl derivative of the present invention against the amount of tears secreted in normal rabbits.

Fig. 4 shows a figure relating to the effect of carbostyryl derivative of the present invention against the proliferation of the cornea epithelium cells in normal rabbits.

Fig. 5 shows a figure relating to the effect of carbostyryl derivative of the present invention against the mucoid capsulitis in normal rabbits determined by a method of Rose Bengal score.

Fig. 6 shows a figure relating to the effect of carbostyryl derivative of the present invention against injury of the corneal epithelium in normal rabbits caused by preventing of blinking.

Fig. 7 shows a figure relating to the effect of carbostyryl derivative of the present invention against the increased amount of mucoid substance covering the conjunctiva in normal rabbits of which the

mucoid layer was removed and determined by an Alcian blue blinding method.

DISCLOSURE OF THE INVENTION

As the results of extensive research work, 5 the present inventors have found the facts that carbostyryl derivatives represented by the general formula (I), particularly among of these, 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid or a salt thereof possess the effect for increasing the 10 number of the goblet cells, the effect for increasing secretion of mucus of the front of the eye, the effect for accelerating proliferation of the corneal epithelium cells, as well as the effect for increasing secretion of tear fluid, thus said carbostyryl derivative is useful as an agent for curing xerophthalmia 15 syndrome, and finally the present invention has been completed.

Carbostyryl derivatives represented by the general formula (I), particularly among of these, 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid or a salt thereof increases the production of ophthalmological mucin by increasing the number of goblet cells, as the results said compound prevents decreasing the amount of mucin in case of the "dry eye" 20 syndrome, while said compound of the present invention increases the amount of mucus of the eye as to maintain the aqueous layer in the tear fluid. Further, said 25

compound of the present invention shows the effect for increasing the amount of tear fluid, thus said compound of the present invention is useful as an agent for curing the "dry eye" syndrome. Additionally, said 5 compound of the present invention is an agent useful not only for curing Sjögren's syndrome and Stevens-Johnson syndrome, which shows the dry eye symptom, but also useful as an agent for preventing and/or curing the second disease (deuteropathy) caused by the "dry 10 eye" symptoms or various ophthalmological diseases which are resulted from decreasing the number of goblet cells and lowering the amount of mucus. In case of the "dry eye" symptom, the eye is very sensitive to be injured, because the surface of the eyeball is dried. 15 In this connection, the compound of the present invention is useful as the active ingredient to be contained in an agent for curing the wound of the surface of the eye, particularly an agent for curing wound of the corneal epithelium or an agent for intraocular perfusion and agent for washing used in ophthalmological 20 operations (including operations of cataract, the vitreous body and glaucoma), because the compound has the effect for accelerating the proliferation of the corneal epithelium cells.

25 An agent for curing ophthalmological diseases of the present invention can be prepared into various forms of common pharmaceutical preparations by formulating the carbostyryl derivative represented by the

general formula (I) or salt thereof as the effective ingredient. Such forms of pharmaceutical preparations are prepared by formulating the carbostyryl derivative (I) with diluents or excipients, for example, fillers, 5 extenders, binders, wetting agents, disintegrants, surfactants, lubricants and the like which are commonly employed.

The pharmaceutical preparations can be shaped into various forms depending upon the curing purposes, 10 thus typical examples of the forms are ophthalmologically acceptable pharmaceutical preparations, such as eye drop preparations and oculentums and the like.

In addition to the eye drop preparations and oculentums, the pharmaceutical preparations can be 15 shaped into tablets, pills, powders, liquid medicines, suspensions, emulsions, granules, capsules, suppositories, injection preparations (liquids, suspensions and the like), aerosol preparations, syrup preparations, preparations for external use and the like. 20 Further, sustained release preparations can also be prepared by formulating with suitable resins.

In case of formulating the pharmaceutical preparations into eye drops, oculentums and the like, they are prepared in accordance with common method 25 by using usual vehicles (diluting agents) acceptable to pharmaceutical preparations for ophthalmological use. Thus, they are prepared by mixing the effective ingredient with a suitable diluting agent, then the

mixture is subjected to sterilizing treatment.

For example, in case of preparing oculentums, various base materials which are widely used in this field, such as emulsion type ointment base, water-soluble type ointment base, suspension type ointment base and the like can be employed. As to typical examples of these base materials, white petrolatum, refined lanolin, liquid paraffin and the like can be exemplified. In case of producing eye drop preparations, sterilized distilled water can be employed as typical diluting agent.

If necessary, a dissolving additive, a buffering agent, an antioxidant, a preservative, an isotonic agent, a pH-controlling agent and the like can be formulated with an pharmaceutical preparation applicable for ophthalmological purpose. As to the dissolving additives, carboxymethyl cellulose-Na; polyoxyethylene glycol ethers, such as polyoxyethylene lauryl ether, polyoxyethylene oleyl ether and the like; polyethylene glycol higher fatty acid esters, such as polyethylene glycol monolaurate, polyethylene glycol monooleate and the like; polyoxyethylene sorbitan monolaurate; polyoxyethylene fatty acid esters and the like can be exemplified. As to the buffering agents, sodium phosphates, sodium hydrogen phosphate, potassium hydrogen phosphate, nitric acid, sodium nitrate, citric acid, sodium citrate, tartaric acid, sodium tartarate, acetic acid, sodium acetate, α -aminocaproic acid,

sodium glutamate and the like can be exemplified. As to the antioxidants, sodium sulfite, sodium pyrosulfite, sodium bisulfite, sodium thiosulfite, ascorbic acid and the like can be exemplified. As to the preservatives, chlorobutanol, benzalkonium chloride, benzethonium chloride, phenylmercury salts, thimerosal, phenethyl alcohol, methylparaben, propylparaben and the like can be exemplified. As to the isotonic agents, sodium chloride, glucose, D-mannitol, glycerin and the like can be exemplified. As to the dissolving agents, N-methyglucamine can be employed. As to the pH-controlling agents, sodium hydroxide, hydrochloric acid and the like can be exemplified.

For the purpose of shaping into the form of tablets, any known carriers which are used widely in this field can be applied, for example, excipients such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid and the like; binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinyl pyrrolidone and the like; disintegrators such as dry starch, sodium alginate, agar powder, laminarin powder, sodium hydrogen-carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, monoglycerides of stearic acid, starch, lactose and the

like; disintegration inhibitors such as white sugar, stearin, cacao butter, hydrogenated oils and the like; absorption accelerators such as quaternary ammonium base, sodium lauryl sulfate and the like; humectants such as glycerin, starch and the like; adsorbents such as starch, lactose, kaolin, bentonite, colloidal silicic acid and the like; lubricants such as refined talc, stearic acid salts, boric acid powder, polyethylene glycols and the like. In case of necessity, the tablets can be prepared in the form of common coated tablets, for example, sugar-coated tablets, gelatin film-coated tablets, enteric film-coated tablets, film-coated tablets, or in the form of double-layers tablets, multiple-layers tablets and the like.

For the purpose of shaping into the form of pills, any known carriers which are widely used in this field can be applied, for example, excipients such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oils, kaolin, talc and the like; binders such as arabic gum powder, tragacanth gum powder, gelatin, ethanol and the like; and disintegrators such as laminarin, agar-agar and the like can be exemplified.

For the purpose of shaping into the form of suppositories, any known carriers which are widely used in this field can be applied, for example, polyethylene glycols, cacao butter, higher alcohols, esters of higher alcohol, gelatin, semi-synthesized glycerides and the like can be exemplified.

For the purpose of shaping into the form of injection preparations, they can be prepared to solutions, emulsions or suspensions. Generally they are sterilized and preferably made isotonic to the

5 blood. In preparing the injection preparations as in the form of solutions, emulsions or suspensions, any known diluents which are widely used in this field can be applied. For example, water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated

10 isostearyl alcohol, fatty acid esters of polyoxyethylene sorbitan and the like can be exemplified. In the case of make the injection preparations isotonic to the blood, sufficient amount of sodium chloride, glucose or glycerin may be contained therein.

15 Additionally, a dissolving adjuvant, a buffer solution, an analgesic agent and the like which are commonly used may be contained therein. In case of necessity, a coloring agent, a preservatives, a perfume, a flavoring agent, a sweetening agent and other medicines may be

20 contained therein.

External preparations are prepared in the form of common pharmaceutical preparations for external use. As to common pharmaceutical preparations for external use are including, for example, a liquid

25 medicine, a medicinal oil, a lotion, a liniment, an oleoginous ointment, an emulsion type ointment, such as O/W type hydrophilic ointment and W/O type water-absorbing ointment, a water-soluble ointment, a pasta,

a plaster, a patch, a cream, an emulsion and the like, and these forms of pharmaceutical preparations for external use are not restricted within the scope of these examples. Each one of these forms of pharmaceutical preparations for external use can be prepared by common methods.

In shaping of these external preparations, various base materials which are widely used in this field can be also applied. For example, at least one oleoginous base can be used singly, or mixture of two or more of them can be used widely; or at least one water-soluble ointment base can be used singly, or mixture of two or more of them can be used widely. Concrete examples of these ointment base are fats and oils such as peanut oil, sesame oil, soybean oil, safflower oil, avogado oil, sunflower oil, corn oil, rapeseed oil, cotton seed oil, castor oil, camellia oil, coconut oil, olive oil, poppy seed oil, cacao butter, beef tallow, lard, wool fat and the like; modified bases obtained by subjecting these fats and oils to chemical changes such as hydrogenation; mineral oils such as petrolatum, paraffin, silicone oil, squalane and the like; higher fatty acid esters such as isopropyl myristate, *n*-butyl myristate, isopropyl linoleate, acetyl ricinoleate, stearyl ricinoleate, propyl ricinoleate, isopropyl ricinoleate, isobutyl ricinoleate, heptyl ricinoleate, diethyl sebacate and diisopropyl adipate; higher aliphatic alcohols such as

cetyl alcohol and stearyl alcohol; waxes such as bleached bees wax, spermaceti, Japan wax, lanolin, carnauba wax, shellac wax and the like; higher fatty acids such as stearic acid, oleic acid, palmitic acid
5 and the like; mixtures of mono-, di- and tri-glycerides of saturated or unsaturated fatty acids having 12 to 18 carbon atoms; polyhydric alcohols such as ethylene glycols, polyethylene glycols, propylene glycol, polypropylene glycols, glycerin, batyl alcohol,
10 pentaerythritol, sorbitol, mannitol and the like; gummy substances such as arabic gum, benzoic gum, guaiacum, tragacanth gum and the like; water-soluble natural high molecular compounds such as gelatin, starch, casein, dextrin, pectin, sodium pectate, sodium alginate,
15 methyl cellulose, ethyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, nitrocellulose, crystalline cellulose and the like; water-soluble synthetic high molecular compounds such as polyvinyl alcohol, poly(vinyl methyl
20 ether), polyvinyl pyrrolidone, sodium polyacrylate, carboxyvinyl polymer, polyethyleneimine and the like; nonionic, anionic, amphoteric and cationic surfactants; ethanol, isopropanol and water, can be exemplified.

To the pharmaceutical preparations for
25 external use, there can be added common additives such as a gelling agent, a preservative, an antioxidant, a buffer solution, a pH controlling agent, a wetting agent, an antiseptic agent, a coloring agent, a

flavoring agent, a pigment, a thickening agent, a metal chelating agent and the like.

Aerosol type preparations can be prepared generally by formulating a sterilized solution or 5 suspension of the carbostyryl derivative of the general formula (I) with a propellant. In case of shaping in the form of a solution or suspension, any one of known diluents which are commonly used in this field can also be used, thus the diluents which are exemplified in 10 formulating the injection preparations can be used. As to the propellant, any one of the propellants which are commonly used in this field can also be used, thus, liquefied gas propellants such as chlorofluorocarbons like dichlorodifluoromethane or trifluorodichloro- 15 ethane; compressed gas propellants such as nitrogen gas, carbon dioxide gas and the like can be exemplified. The aerosol type preparations may further contain a common solubilizing adjuvant, a buffering agent, and the like, and if necessary, a coloring agent, a preservative, a perfume, a flavoring agent, a 20 sweetening agent may be added thereto.

The amount of the effective ingredient to be contained in the agents for curing ophthalmological diseases of the present invention is not specifically 25 restricted and can be selected from a wide range, and generally the amount may be selected within the range of from 0.005 to 5 % by weight, preferably 0.01 to 3 % by weight.

Method for administering the agent of the present invention is not specifically restricted. Thus, the agent may be administered by methods similar to those employed in usual pharmaceutical preparations acceptable for ophthalmological use, depending upon the form of preparation, the age of patient, the distinction of sex and other conditions, the degree of disease condition of the patient.

As to a typical method for administration of the agent of the present invention, for example, an oculentum is administered by coating on the eye. An eye drop preparation is administered by a method similar to that of employed in common eye drop preparation, for example, 1 to 2 drops of an eye drop preparation is dropped in the eye from a suitable eye drop container. Further, an eye drop preparation may be administered in the eye by use of a spraying device.

As to other methods for administration of the agent of the present invention, for example, tablets, pills, a liquid preparation, a suspension preparation, an emulsion preparation, a granular preparation, a syrup preparation and a capsule preparation are administered orally. An injection preparation is administered singly or in combination with a common auxiliary solution such as a glucose solution and/or an amino acid solution, intravenously. In case of necessity, the injection preparation is administered singly intramuscularly, intradermally, subcutaneously

or intraperitoneally. A suppository is administered intrarectally.

Dosage of the agent of the present invention may be suitably selected depend upon the method for 5 administration, the age of patient, the distinction of sex, and other conditions, as well as the degree of disease condition of the patient and other related factors, and generally an agent acceptable for ophthalmological use, for example an eye drop or an oculentum 10 is administered 1 to 15 times a day, preferably within a range of 1 to 10 times a day.

EXAMPLES

An agent for curing ophthalmological disease of the present invention will be explained specifically 15 by illustrating an example of pharmaceutical preparation and pharmacological experiments.

Example of pharmaceutical preparation 1

	2-(4-Chlorobenzoylamino)-3-(2-quinolone-4-yl)propionic acid	0.20 g
20	Benzalkonium chloride	0.01 g
	Sodium dihydrogen phosphate	0.56 g
	Potassium dihydrogen phosphate	0.80 g
	Distilled water	q.s.

Each one of the above-mentioned ingredients are dissolved in distilled water, then the resulting solution was sterilized and filtrated by using a suitable filter paper to prepare an agent of the present invention in the form of an eye drop preparation.

5

Pharmacological Test 1

(1) Test liquids

As to the specific example of the effective ingredient of the agents for curing ophthalmological diseases of the present invention, 2-(4-chlorobenzoyl-amino)-3-(2-quinolone-4-yl)propionic acid (hereinafter referred to as the compound of the present invention) was used and prepared the following dissolving liquid and suspension liquid, and used them as test liquids.

15 a) 3% Dissolving liquid

The compound of the

	present invention	3.00 g
	Meglumine (N-Methylglucamine)	2.64 g
	Concentrated glycerin	1.80 g
20	Hydrochloric acid	q.s.
	10% Benzalkonium	0.10 ml
	Water (an adequate amount was added to adjust the whole volume to:)	100 ml

25

pH (the pH value was adjusted to within the
range of:)

8.3 to 9.3

b) 3% Suspension liquid

The compound of the

present invention 3.00 g

Sodium dihydrogenphosphate 0.40 g

5 Disodium hydrogenphosphate 0.47 g

Sodium chloride 0.50 g

Carboxymethyl cellulose-Na 0.20 g

Polysorbate 80 0.16 g

10% Benzalkonium chloride 0.10 ml

10 Water (an adequate amount was
added to adjust the whole
volume to:)

100 ml

pH (the pH value was adjusted to within the

15 range of:) 6.5 to 7.5

On the other hand, physiological saline was
used as the control test in place of the test liquids.

(2) Experimental method and the results

To both eyes of 3 normal rabbits, the
20 above-mentioned test liquid were administered by eye
drop, in an amount of 50 μ l/one eye/one administration.
Each of the test group and the control group consists
of 3 rabbits, thus, 6 eyes were used in each group.
The administration was conducted 4 times a day, and was
25 continued for 2 weeks. After that, each one of the
rabbits was killed, then the following 3 items of tests

were conducted.

(i) Measurement of the amount of mucoid substance covering on the surface of the conjunctiva
(Measurement by Alcian Blue binding method)

5 The above-mentioned normal rabbits were killed, and the whole conjunctivae of the rabbits were enucleated. Next, the enucleated conjunctivae were washed with an ice-cooled aqueous solution of 0.25 M sucrose, and weight of each of the tissue of
10 conjunctivae was measured.

 The conjunctiva thus treated was incubated in 10 ml of 0.1% Alcian Blue solution at room temperature for 1.5 hours, then was washed with an aqueous solution of 0.25 M sucrose for 15 minutes, further washed with
15 the same solution for 45 minutes. The conjunctiva thus obtained was further incubated in 10 ml of an aqueous solution of 0.5 M $MgCl_2$, for 2 hours, so as to extract the colorant being binded with mucoid layer of the conjunctiva. The extract thus obtained was washed with
20 10 ml of diethyl ether, and the optical density of the aqueous layer was measured at 605 nm, and the optical density per weight of the tissue (O.D. unit/g of tissue) was calculated (mean value \pm S.E., n = 4 eyes). The results are shown in Fig. 1.

25 As can be seen from Fig. 1, the amount of the colorant (Alcian blue) being binded with the mucoid substance covering on the conjunctiva of the normal

rabbits of the test group, to which 3% dissolving liquid and 3% suspension liquid (both of them containing the compound of the present invention, respectively) were administered by eye drop, were measured in 5 the larger value as compared with that measured in the rabbits of the control group. Thus, the compound of the present invention shows the effect for increasing the amount of the mucoid substance covering the surface on the conjunctiva.

10 (ii) Measurement of the number of the goblet cells contained in the conjunctiva

(Measurement by method of impression cytology)

The portion of the bulbar conjunctiva, which is located closely to the nasolacrimal duct at the 15 upper position of the eye of the rabbit being treated with the above-mentioned test liquids, was slightly dried, then a piece of millipore filter was put thereon and the filter was impressed to collect samples of the epithelium cells of the conjunctive as well as the 20 goblet cells. The collected cells were fixed with 70% ethanol and were stained by use of periodic acid-Schiff reaction (PAS) and hematoxylin, next the thus stained millipore filter was changed to transparent by use of xylene and was enclosed in the space of a preparative 25 glass. The thus obtained sample in the preparative glass was photo-graphed, and the number of the goblet cells (mean value \pm S.E., n = 4 eyes) per unit area

(0.09 mm²) was calculated. The results are shown in Fig. 2.

As can be seen from Fig. 2, the number of the goblet cells contained on the conjunctiva of the normal rabbits of the test group, to which 3% dissolving liquid and 3% suspension liquid (both of them containing the compound of the present invention, respectively) were administered by eye drop, was measured in the larger value as compared with those measured in the rabbits of the control group. Thus, the compound the present invention shows the effects for increasing the amount of mucoid substance and also increasing the amount of tear fluid as well.

(iii) Measurement of the amount of tear fluid
15 (Measurement by modified method of Schirmer test I)

To the normal rabbits of the test group being treated with the above-mentioned test liquids, 30 µl of Benoxil (a trade name for 0.4% of oxybuprocaine hydrochloride solution for eye drop use, manufactured by Santen Pharmaceutical Co., Ltd.) was administered by eye drop 5 minutes before the following test for measuring the amount of tears fluid. The rabbits were allowed to stand as they are for 4 minutes, and the tear fluid on the surface of the eyes were wiped off. Then, 1 minute after, a piece of Schirmer test paper was put in a space between the inside of the lower

eyelid and the surface of the eye (the start for measuring the amount of tear fluid). The rabbits were allowed to stand as they were for 5 minutes, then the length (mm) (mean value \pm S.E., n = 4 eyes) of tear 5 fluid being permeated on the Schirmer test paper was measured. The results are shown in Fig. 3.

As can be seen from Fig. 3, the amount of tear fluid of the normal rabbits of the test group, to which 3% dissolving liquid and 3% suspension liquid 10 (both of them containing the compound of the present invention, respectively) were administered by eye drop, were measured in larger value as compared with those measured in the rabbits of the control group. Thus, the compound of the present invention shows the effects 15 for increasing the amount of tear fluid as compared with those shown by the rabbit of the control group.

Pharmacological Test 2

(1) Experimental method

The eyeballs were enucleated from New Zealand 20 White female rabbit, and a sample piece of the sclerocornea was prepared. After peeled off the Descemet's membrane and the endotheliocyte from said sample piece under observation by use of a stereoscopic microscope, then the sample piece of the sclerocornea 25 was washed 4 to 5 times with a phosphate buffered physiological saline so as to made the sample as in an aseptic condition (asepsis). Next, said aseptic sample

piece of sclerocornea was soaked in a Dulbecco's modified Eagle's culture medium F12 (DME/F12) (1:1), and about 20 pieces of small square sample blocks having a side of 2 - 3 mm of the cornea were cut out from each 5 one of all of the cornea samples by using a razor blade. Into a tissue culture dish having 60 mm in diameter, 7 to 8 pieces of these small sample blocks of the cornea were put in the dish and adhere the downside of the block to the bottom of the dish so as to keep 10 the corneal epithelium upside, and were cultivated in a culture medium containing 10% FCS, 10 ng/ml of hEGF added-DME/F12 (1:1) under an atmosphere of 5% CO₂-95% air, at 37°C. After 2 days of cultivation, the small sample blocks of the corneal epithelium were took out 15 from the culture medium and the medium was exchanged.

The cultivation was continued for 4 - 5 days (the culture medium was exchanged 1 - 3 times), then the culture medium was removed, the small sample blocks of the corneal epithelium were washed with a phosphate 20 buffer solution, the cells were floated in a solution of 0.1% trypsin - 0.02% EDTA, and was suspended in a culture medium of DME/F12 (1:1) containing 10% FCS, next the suspension was inoculated on a multiwell cultivating dish having 12 wells in an amount of 1 x 25 10⁴ cells/well. After about 12 hours, the culture medium was exchanged to another medium of DME/F12 containing 1% FCS, and the compound of the present invention which was the same as used in Pharmacological

Test 1 was dissolved in DMSO and added in the concentration of 10^{-4} to 10^{-6} M.

48 Hours after the addition of the compound of the present invention, the culture medium containing the compound of the present invention was exchanged.

5 96 Hours after the addition of the compound of the present invention, the cells were floated in a solution of 0.1% trypsin - 0.02% EDTA, and the number of the cells was counted (mean value \pm S.E., n = 6 eyes) by 10 using a Coulter counter.

As to the reference test, sodium hyaluronate (1 mg/ml) was used in place of the compound of the present invention. As to the control test, DMSO without containing a compound of the present invention 15 was used.

(2) Test results

The results are shown in Fig. 4. As can be seen from Fig. 4, in case of treating the corneal epithelium with the compound of the present invention, 20 excellent effect for increasing the proliferation of corneal epithelium was shown as compared with that shown in the reference test by using sodium hyaluronate which is recognized as a compound having the activity for increasing the proliferation of corneal epithelium.

25 In the Fig. 4, the symbol "*" means $p < 0.05$ vs control; and the symbol "**" means $p < 0.01$ vs control.

Pharmacological Test 3

(Test of the dry eye model prepared by compulsive blowing)

(1) Test liquid

5 As to the specific example of the effective ingredient of the agents for curing ophthalmological diseases of the present invention, 2-(4-chlorobenzoyl-amino)-3-(2-quinolone-4-yl)propionic acid (hereinafter referred to as the compound of the present invention) 10 was used and prepared the following 1% eye drop liquid, and used it as test liquid.

1% Eye drop liquid

The compound of the present invention 0.50 g

Meglumine (N-Methylglucamine) 1.32 g

15 Concentrated glycerin 0.45 g

10% Benzalkonium 50 μ l

Physiological saline (an adequate

amount was added to adjust the

whole volume to:) 50 ml

20

pH (the pH value was adjusted to

within the range of:) 8.8 to 9.3

Osmotic pressure (the osmotic pressure

was adjusted to within the range

25 of:) 290 to 300 mOsm

As to the control test, the above-mentioned

dissolving agent of the eye drop without containing a compound of the present invention was used as the reference.

(2) Method for preparing the dry eye model (the 5 mucoid capsulitis and injury of cornea epithelium)

A New Zealand White female rabbits were used for the test. The nictitating membrane of the rabbit was excised before the test.

10 To both eyes of the rabbit was administered, as anesthetics, by injecting in the muscle with 200 mg/body weight of Ketamin hydrochloride and dropping 4% of oxybuprocaine hydrochloride solution in the dosage of 2 drops/eye.

15 The distance between a dryer and the cornea was kept in 10 cm, and wind was blown from the dryer to the direction in front of the cornea for 10 minutes. The tear fluid was evaporated, and the surface of the cornea was dried, then the mucoid capsulitis and 20 injury of cornea epithelium were induced thereby.

(3) Administration of the test compound

25 Two weeks before conducting the wind blowing from the dryer, the 1% eye drop liquid was administered. After preparation of the dry eye model by wind blowing from the dryer, the 1% eye drop liquid was administered for 2 weeks. Administrations of the 1%

eye drop liquid were conducted 4 times/day at intervals of 2.5 hours before and after the administrations.

As to the control test, the dissolving agent of the eye drop without containing a compound of the present invention was used as the reference.

(4) Evaluation method and the results

Results of the test were evaluated regarding the following 2 items in connection with before administration with the 1% eye drop liquid; before conducting the wind blowing; 1, 4, 7, 10 and 14 days after the wind blowing.

(i) Score evaluation of the injured cornea by method of intravital staining with Rose Bengal colorant

The cells of the cornea which were not covered with mucoid substance were stained by method of intravital staining with Rose Bengal colorant, and the mucoid capsulitis on the cornea of the rabbit of the test group were evaluated on the basis of the following score evaluations according to the stained degree of the cornea (mean value \pm S.E., n = 10 eyes).

Score evaluations (Perfect score: 3 points)

Score 0: The cornea was not stained at all.

5

Score 1: Less than 1/3 of the area of the all cornea was stained uniformly, or less than 2/3 of the area of the cornea was stained spots.

10

Score 2: 1/3 - 2/3 of the area of the all cornea was stained uniformly, or more than 2/3 of the area of the cornea was stained spots; or less than 1/3 of the area of the all cornea was stained uniformly, also stained spots was observed.

15

Score 3: More than 2/3 of the area of the all cornea was stained uniformly, or 1/3 - 2/3 of the area of the all cornea was stained uniformly, also stained spots were observed.

The results are shown in Fig. 5. As can be seen from Fig. 5, the cornea of the New Zealand White rabbits of the test group, to which the 1% eye drop liquid were administered, the score of intravital staining with Rose Bengal colorant are lower than those shown by the control group. Thus, the compound of the present invention significantly inhibits and cures the mucoid capsulitis caused by wind blowing method.

(ii) Score evaluation of the injured cornea by method of intravital staining with fluorescein-Na colorant

Defective portion of the cells and abnormal portion of the intercellular space were stained by method of intravital staining with fluorescein-Na colorant, and the mucoid capsulitis on the cornea of the rabbit of the test group was evaluated on the basis of the scores according to the stained degree of the cornea similar to those employed in the above-mentioned intravital staining with Rose Bengal colorant (mean value \pm S.E., n = 10 eyes).

As a result, comparing with the fluorescein score at 1 day after the wind blowing, the score of the control group was 2 or more, while the score of the New Zealand White rabbits of the test group, to which the 1% eye drop liquid were administered, was almost 1. Thus, the compound of the present invention significantly inhibits and cures mucoid capsulitis induced by wind blowing method.

Pharmacological Test 4

(Test of the dry eye model prepared by preventing of blinking)

(1) Test liquid

1% Eye drop liquid (eye drop liquid containing 1% of the compound of the present invention), which is similar to the one employed in Pharmacological Test

3, was used as the test liquid.

As to the control test, dissolving agent of the eye drop without containing a compound of the present invention was used.

5 (2) Method for preparing the dry eye model

A New Zealand White female rabbits were used for the test. The nictitating membrane of the rabbit was excised before the test.

To both eyes of the rabbit was administered, 10 as anesthetic, by injecting in the abdominal cavity with 2 g/body weight of uretan. The eyelids of the rabbit were compulsively kept open by use of an eye speculum, and were allowed to stand as they were at 25°C for 2 hours. The tear fluid was evaporated, and 15 the surface of the cornea was dried, an injured cornea epithelium as the dry eye model of was prepared.

(3) Administration of the test compound

Two weeks before the preventing of blinking, the 1% eye drop liquid was administered 4 times/day at 20 intervals of 2.5 hours. The final administration with the eye drop liquid was conducted 5 minutes before the preventing of blinking.

As to the control test, the dissolving agent of the eye drop without containing a compound of the 25 present invention was used as the reference.

(4) Evaluation method and the results

After finished the preventing of blinking, 50 μ l of 1% methylene blue solution was administered by eye drop of the rabbit of the test group, and the eye 5 was washed thoroughly with a physiological saline.

Then, the rabbit was killed by intravenous administration with an excessive amount of pentobarbital injection solution, and the cornea was enucleated. The methylene blue was extracted from the 10 enucleated cornea by using a mixture of acetone : an aqueous solution saturated with sodium sulfate = 7:3 by taking time for overnight. Optical density at 660 nm of the thus obtained extract was measured, and the methylene blue being stained to the injured portion of 15 the cornea epithelium was calculated (mean value \pm S.E., n = 8 eyes).

Results are shown in Fig. 6. As can be seen from the Fig. 6, the compound of the present invention inhibits the injury of the corneal epithelium induced 20 by preventing of blinking.

Pharmacological Test 5

(Test of the dry eye model prepared by removal of the mucoid layer from the conjunctiva)

(1) Test liquid

25 1% Eye drop liquid (eye drop liquid containing 1% of the compound of the present invention), which is similar to the one employed in Pharmacological Test

3, was used as the test liquid.

As to the control test, dissolving agent of the eye drop without containing a compound of the present invention was used.

5 (2) Method for preparing the dry eye model

The dry eye model was prepared by dissolving and removing the mucoid layer from the conjunctiva of a New Zealand White female rabbit by instillation with an N-acetylcysteine solution of 10% in concentration, 10 by means of eye drop 6 times at intervals of 2 hours for 1 day.

(3) Administration of the test compound

1% Eye drop liquid was administered 4 times/day at intervals of 2.5 hours and were continued 15 for 2 weeks.

As to the control test, the dissolving agent of eye drop liquid without containing a compound of the present invention was used as the reference.

(4) Evaluation method and the results

20 2 Weeks after the beginning of administration of the 1% eye drop liquid, the rabbit was killed by intravenous administration of an excessive amount of pentobarbital injection solution, then the cornea was enucleated. The amount of the mucoid substance 25 covering on the conjunctiva was measured by a procedure


similar to that employed in Alcian Blue binding method in Pharmacological Test 1, (2) (i) (mean value \pm S.E., n = 6 eyes).

The results are shown in Fig. 7. As can be seen from Fig. 7, the amount of the colorant binded onto the mucoid substance covering on the conjuctiva in the New Zealand White rabbits of the test group, to which the 1% eye drop liquid were administered, the amount of the mucoid substance covering on the conjuctiva are higher than those shown by control group. Thus, the compound of the present invention increases the amount of the mucoid substance covering on the conjuctiva up to almost the same level as on the surface of the eyes in normal state.


In Fig. 7, the symbol "#" means $p < 0.05$ vs. the eyes in normal state (t-test); and the symbol "##" means $p < 0.01$ vs. the eyes of control group (t-test).

CLAIMS

1. An agent for curing ophthalmological diseases which contains, as the active ingredient, a carbostyryl derivative or salt thereof represented by the general 5 formula (I),



(wherein R is a halogen atom, the substituted position of the side-chain of the formula,




is 3- or 4-position in the carbostyryl skeleton, and 10 the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or a double bond).

2. The agent for curing ophthalmological diseases according to Claim 1, which is an agent for 15 accelerating proliferation of the goblet cells in the eye.


3. The agent for curing ophthalmological diseases according to Claim 1, which is an agent for increasing the amount of mucoid substance secreted in the eye.
- 5 4. The agent for curing ophthalmological diseases according to Claim 1, which is an agent for increasing the amount of tear fluid secreted in the eye.
- 10 5. The agent for curing ophthalmological diseases according to Claim 1, wherein the ophthalmological disease is xerophthalmia (dry eye) syndrome.
6. The agent for curing ophthalmological diseases according to Claim 1, which is an agent for curing injury of the eye.
- 15 7. The agent for curing ophthalmological diseases according to Claim 6, wherein the injury of the eye is an injury of corneal epithelium.
8. The agent for curing ophthalmological diseases according to any one of Claims 1 to 7, wherein 20 the effective ingredient is 2-(4-chlorobenzoylamino)-3-(2-quinol-4-yl)propionic acid or a salt thereof.
9. The agent for curing ophthalmological diseases according to Claim 8, which is in the form of a pharmaceutical preparation suitable for ophthalmological application.
- 25 10. A pharmaceutical preparation suitable for ophthalmological application which contains 2-(4-chlorobenzoylamino)-3-(2-quinol-4-yl)propionic acid

or a salt thereof together with usual vehicles (diluents or excipients) acceptable to pharmaceutical preparations for ophthalmological applications.

11. Method for treating ophthalmological diseases
5 by using an agent for curing ophthalmological diseases
which contains, as the active ingredient, a carbostyryl
derivative or salt thereof represented by the general
formula (I),



(wherein R is a halogen atom, the substituted position of the side-chain of the formula,



is 3- or 4-position in the carbostyryl skeleton, and the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or a double bond).

12. Method for treating ophthalmological diseases

by using the agent for curing ophthalmological diseases according to Claim 11, which is an agent for accelerating proliferation of the goblet cells in the eye.

13. Method for treating ophthalmological diseases
5 by using the agent for curing ophthalmological diseases according to Claim 11, which is an agent for increasing the amount of mucoid substance secreted in the eye.

14. Method for treating ophthalmological diseases by using the agent for curing ophthalmological diseases
10 according to Claim 11, which is an agent for increasing the amount of tear fluid secreted in the eye.

15. Method for treating xerophthalmia (dry eye) syndrome by using the agent for curing ophthalmological diseases according to Claim 11.

15 16. Method for treating ophthalmological diseases by using the agent for curing ophthalmological diseases according to Claim 11, which is an agent for curing injury of the eye.

17. Method for treating an injury of corneal
20 epithelium by using the agent for curing ophthalmological diseases according to Claim 16.


18. Method for treating ophthalmological diseases by using the agent for curing ophthalmological diseases according to any one of Claims 11 to 17, wherein the
25 effective ingredient is 2-(4-chlorobenzoylamino)-3-(2-quinolone-4-yl)propionic acid or a salt thereof.

19. Method for treating ophthalmological diseases by using the agent for curing ophthalmological diseases


according to Claim 18, which is in the form of a pharmaceutical preparation suitable for ophthalmological application.

20. Method for treating ophthalmological diseases
5 by using a pharmaceutical preparation suitable for ophthalmological application which contains 2-(4-chlorobenzoylamino)-3-(2-quinolone-4-yl)propionic acid or a salt thereof together with usual vehicles (diluents or excipients) acceptable to pharmaceutical 10 preparations for ophthalmological applications.

21. Use of a compound for preparing an agent for curing ophthalmological diseases which contains, as the active ingredient, a carbostyryl derivative or salt thereof represented by the general formula (I),



(wherein R is a halogen atom, the substituted position of the side-chain of the formula,



is 3- or 4-position in the carbostyryl skeleton, and

the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single bond or a double bond).

22. Use of a compound for preparing the agent for 5 curing ophthalmological diseases according to Claim 21, which is an agent for accelerating proliferation of the goblet cells in the eye.

23. Use of a compound for preparing the agent for curing ophthalmological diseases according to Claim 21, 10 which is an agent for increasing the amount of mucoid substance secreted in the eye.

24. Use of a compound for preparing the agent for curing ophthalmological diseases according to Claim 21, which is an agent for increasing the amount of tear 15 fluid secreted in the eye.

25. Use of a compound for preparing the agent for curing xerophthalmia (dry eye) syndrome according to Claim 21.

26. Use of a compound for preparing the agent for 20 curing ophthalmological diseases according to Claim 21, which is an agent for curing injury of the eye.

27. Use of a compound for preparing the agent for curing ophthalmological diseases according to Claim 26, which is an agent for curing injury of the corneal 25 epithelium.

28. Use of a compound for preparing the agent for curing ophthalmological diseases according to any one of Claims 21 to 27, wherein the effective ingredient is

2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid or a salt thereof.

29. Use of a compound for preparing the agent for curing ophthalmological diseases according to Claim 28, 5 which is in the form of a pharmaceutical preparation suitable for ophthalmological application.

30. Use of a pharmaceutical preparation suitable for ophthalmological application which contains 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid or a salt thereof together with usual vehicles (diluents or excipients) acceptable to pharmaceutical 10 preparations for ophthalmological applications.





AMOUNT OF MUCOID SUBSTANCE BINDED WITH
ALCIAN BLUE (O.D. UNIT/g OF THE TISSUE)1 / 5
FIG. 1NUMBER OF THE GOBLET CELLS
(PER UNIT AREA OF 0.09 mm²)


FIG. 2





3 / 5


FIG. 5



* : $p < 0.05$ VS CONTROL
(ANALYSIS OF VARIANCE ON THE
BASIS OF DATA OBTAINED FROM
REPEATED MEASUREMENTS)


4 / 5

FIG. 6



5 / 5

FIG. 7



INTERNATIONAL SEARCH REPORT

International Application No
PLT/JP 96/02850

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 95 11026 A (OTSUKA PHARMA CO LTD ;MATSUDA TAKAHIDE (JP); OWADA SHIGERU (JP); M) 27 April 1995 see abstract see page 3, line 20 - line 23 see page 14, line 26 - page 15, line 2; claims; example 3</p> <p>---</p>	1-14, 16, 18-30
X	<p>WO 93 23043 A (OTSUKA PHARMA CO LTD ;YAMASAKI KATSUYA (JP); SAKURAI KAZUSHI (JP)) 25 November 1993 cited in the application see abstract; claims; example 3</p> <p>---</p> <p>-/-</p>	1-10, 21-30



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- '&' document member of the same patent family

Date of the actual completion of the international search

30 January 1997

Date of mailing of the international search report

06.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Hoff, P

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 96/02850

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 543 018 A (OTSUKA PHARMA CO LTD) 26 May 1993 cited in the application see abstract; claims; examples & WO 92 21342 A (OTSUKA PHARMA) ---	1-10, 21-30
X	GB 2 123 825 A (OTSUKA PHARMA CO LTD) 8 February 1984 cited in the application see abstract see page 116, line 4 - line 19; claims & JP 63 035 623 A (OTSUKA PHARMA) ---	1-10, 21-30
P,A	WO 96 04911 A (OTSUKA PHARMA CO LTD ;KITAZAWA TOSHIKI (JP); FUJISAWA SHIGEKI (JP)) 22 February 1996 see the whole document ---	1-30
A	WO 94 21612 A (OTSUKA PHARMA CO LTD ;SAKAMOTO MAKOTO (JP); IMAOKA TAKESHI (JP); M) 29 September 1994 see pharmaceutical example 2 on page 214 see abstract; claims 1,23 -----	1-30

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 96/02850

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 11-20 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 96/02850

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9511026	27-04-95	AU-A-	7864194	08-05-95
		CA-A-	2150546	27-04-95
		CN-A-	1117268	21-02-96
		EP-A-	0674515	04-10-95
		JP-A-	8012578	16-01-96
<hr/>				
WO-A-9323043	25-11-93	AU-B-	657412	09-03-95
		AU-A-	4022993	13-12-93
		EP-A-	0594867	04-05-94
		JP-T-	6509587	27-10-94
		US-A-	5476858	19-12-95
<hr/>				
EP-A-0543018	26-05-93	AU-B-	645690	20-01-94
		AU-A-	1783392	08-01-93
		CA-A-	2088582	08-12-92
		DE-D-	69207560	22-02-96
		DE-T-	69207560	27-06-96
		WO-A-	9221342	10-12-92
		JP-A-	5148143	15-06-93
		US-A-	5480891	02-01-96
<hr/>				
GB-A-2123825	08-02-84	JP-C-	1490120	07-04-89
		JP-A-	59007168	14-01-84
		JP-B-	63035623	15-07-88
		JP-C-	1665247	19-05-92
		JP-B-	3028425	19-04-91
		JP-A-	59007169	14-01-84
		AT-B-	385506	11-04-88
		AU-B-	552717	19-06-86
		AU-A-	1653683	12-01-84
		BE-A-	897208	04-01-84
		CA-A-	1247624	27-12-88
		CH-A-	654578	28-02-86
		DE-A-	3324034	05-01-84
		DK-B-	168288	07-03-94
		FR-A-	2530626	27-01-84
		NL-A-	8302390	01-02-84
		SE-B-	462848	10-09-90
		SE-A-	8303813	06-01-84
		US-A-	4578381	25-03-86

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inv. Total Application No

PCT/JP 96/02850

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB-A-2123825		US-E-	RE34722	06-09-94

WO-A-9604911	22-02-96	AU-A-	3191795	07-03-96
		JP-A-	8104630	23-04-96

WO-A-9421612	29-09-94	AU-B-	672888	17-10-96
		AU-A-	6263794	11-10-94
		CA-A-	2136108	29-09-94
		CN-A-	1105799	26-07-95
		EP-A-	0641323	08-03-95
		JP-A-	7157470	20-06-95
		US-A-	5594006	14-01-97
